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Genotoxins cause DNA damage, which can result in genomic instability. The genetic changes induced have
far-reaching consequences, often leading to diseases such as cancer. A wide range of genotoxins exists,
including radiations and chemicals found naturally in the environment, and in man-made forms created by
human activity across a variety of industries. Genomic technologies offer the possibility of unravelling the
mechanisms of genotoxicity, including the repair of genetic damage, enhancing our ability to develop, test
and safely use existing and novel materials. We have developed 3D-DIP-Chip, a microarray-based method
tomeasure the prevalence of genomic genotoxin-induced DNA damage.We demonstrate themeasurement
of both physical and chemical induced DNA damage spectra, integrating the analysis of these with the
associated changes in histone acetylation induced in the epigenome. We discuss the application of the
method in the context of basic and translational sciences.
T
heDNAmolecule is highly susceptible to damage from a variety of genotoxins, both natural andman-made.
Endogenous DNA damage occurs spontaneously, at high rates, as a consequence of normal cellular pro-
cesses including oxidative reactions, resulting in DNA basemodifications, and a variety of errors introduced
during DNA replication. Exogenous DNA damage occurs due to chemical or physical insults, including radia-
tions present in the environment and man-made chemicals. These often induce the formation of bulky adducts,
cross-links and strand breaks in theDNA, which if not repaired correctly can lead to cell death or the proliferation
of mutations. To ensure cell survival and to maintain the integrity of the genome, sophisticated networks of DNA
repair pathways have evolved. These are critical to maintaining health and preventing genetic mutations, which
may result in disease development and drive carcinogenesis.
Mutations induced in DNA by genotoxic agents are a product of DNA damage caused by exposure of cells
to those agents, and the cells’ capacity to subsequently repair that damage. The ability to sensitively measure
genome-wide levels and locations of genetic damage, and rates of its removal by DNA repair, has major
significance in a range of applications. In addition to determining the mechanisms of DNA damage induc-
tion and DNA repair processes in basic research, such a method may be employed in a variety of other
settings. For example, current genotoxicity testing uses overly simplistic assays, often relying on animal
models1. Novel in vitro methods are being developed and a microarray-based tool for measuring DNA
damage and repair would represent a significant advance in this area. Similarly, clinicians using DNA
damaging chemotherapeutic drugs — mainstays in the treatment of patients with solid tumours — would
benefit enormously from a method capable of predicting response to these agents based on the detection of
genomic DNA damage and repair signatures. The development of such a method would represent an
important advance and would enable personalisation of therapies. Recent advances in DNA sequencing
technologies now permit whole genome mutation analyses, and the sequencing of individual cancer genomes
has revealed the presence of mutational signatures within the genomes of cancer cells2. The ability to detect
and measure DNA damage and repair spectra with a view to associating these with the mutational end-points
detected in cancer genomes would enable these early indicators to be used as predictive markers for the
subsequent mutational endpoints. These may include markers which predict predisposition to, and the
progression of, disease, as well as the ability to determine the response of individuals to drug treatments
of these diseases.
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Here we present and, importantly, validate a novel, patented
method to measure the locations and levels of genotoxin-induced
DNA damage throughout genomes, or sections thereof, named 3D-
DIP-chip: DNA Damage Detection (3D) by DNA Immuno-
Precipitation (DIP) on microarray chips (Chip). We describe for
the first time the definitive protocols for the use of this method in
both yeast and human cells. This method enables the examination
and mapping of DNA damage at a high resolution throughout any
sequenced genome (Figure 1). We demonstrate the technology with
DNA damage induced by three genotoxins: a natural physical source
(UV radiation) and two synthetic chemical sources (the platinating
chemotherapeutic drugs cisplatin and oxaliplatin) in cultured
human cells and in Saccharomyces cerevisiae.
We also demonstrate how these 3D-DIP-Chip datasets may be
examined in association with additional ChIP-chip datasets to carry
out integrated analyses of a variety of different data. In the work
presented here we investigate histone H3 lysine 14 (H3K14) acetyla-
tion changes in response to these DNA damaging agents using ChIP-
chip in S. cerevisiae. Epigenetic changes in histone H3 acetylation are
known to be an important cellular response to DNA damage, con-
trolling the chromatin structure in the nuclei of cells, promoting
efficient DNA repair3,4. We compare these epigenetic changes
induced by UV and platinum DNA adduct formation in cells in
the context of the respective DNA damage spectra. We demonstrate
how the integrated analysis of these related datasets, which is made
possible via the bioinformatic software package Sandcastle developed
in our laboratory, reveals the potential for gaining a systems view of
genome stability, revealing how organisms organise and orchestrate
their responses to genetic damage.
Results
Workflow.The 3D-DIP-Chip experimental workflow is described in
detail in theMethods section of this report. The procedure is outlined
in Figure 1. Briefly, protein cross-linked chromatin or damagedDNA
is extracted from cells and fragmented by sonication (Figure 1a, top
and bottom respectively). Fragments of interest are affinity captured
by immunoprecipitation (IP) using an antibody raised against that
feature of interest, for example a damage induced DNA adduct, a
DNA binding protein or a post-translationally modified histone
(Figure 1b). Initial input (IN) samples are also collected. Following
IP, DNA damages or DNA-protein cross-links are reversed, DNA is
purified and IP and IN samples are amplified, differentially labelled
using a two-dye system and applied to DNA microarrays covering
the genome of interest (Figure 1c). After hybridisation the micro-
arrays are washed and optically scanned (Figure 1d), and the
fluorescence intensity values recorded for each probe representing
a location of the genome are converted to numerical values, which
can be analysed and plotted (Figure 1e). The data from these files are
loaded into the R statistical programming environment (R Develop-
ment Core Team. R: A language and environment for statistical
computing. R foundation for statistical computing (Vienna, Austria,
2011)) for analysis, and analysed using Sandcastle, a suite of tools for
the normalisation, analysis and graphical display of ChIP-chip data.
The Sandcastle software and full documentation are available for
download from http://reedlab.cardiff.ac.uk/sandcastle
Affinity capturing damaged DNA.Monoclonal antibodies for UV-
induced CPDs and platinum-induced guanine adducts were used to
affinity capture DNA damaged with the respective agents, with the
resulting enrichment assessed by Q-PCR (full details are given in the
Methods section). Dose-dependent enrichment is demonstrated for
DNA from both yeast and human cells treated with cisplatin and
oxaliplatin (Supplementary Fig. S1 a and b respectively), confirming
the known characteristic that oxaliplatin forms fewer adducts than
cisplatin at equimolar doses5–7. This demonstrates that 3D-DIP is a
reliable method of affinity capturing DNA damaged by different
genotoxins.
Removing DNA damage lesions prior to PCR amplification. The
IN and 3D-DIP samples contain DNA damage. Many DNA adducts,
including CPDs and platinum adducts, inhibit DNA polymerases8,9
which can restrict efficient downstream processing of samples by
PCR. Removal of the damage is therefore required to carry out the
full 3D-DIP-Chip procedure. Platinum-DNA adducts are very stable
over a long period of time, but in the presence of cyanide ions most
platinum residues are known to be removed from DNA10. Sodium
cyanide (NaCN) has been proven to be the most effective chemical
for disrupting platinum-DNA adducts10–12, and in the DIP studies
described in this paper, NaCNwas used to remove platinum adducts.
Similarly, CPDs also need removal prior to downstream processing
and this was achieved using a PreCR DNA repair kit (See Methods
for details). Supplementary Fig. S2a demonstrates the effectiveness of
NaCN in removing adducts from cisplatin and oxaliplatin treated
human DNA. Platinum damaged DNA treated with NaCN prior to
immunoprecipitation shows no enrichment following immunopre-
cipitation, demonstrating removal of the platinum adducts. Effective
DNA damage removal following immunoprecipitation of platinum
induced adducts was also confirmed by demonstrating greater qRT-
PCR amplification in DNA samples processed for damage removal
after immunoprecipitation (Supplementary Fig. S2 b and c).
Figure 1 | Representation of the 3D-DIP-Chip and ChIP-Chip
procedure. (a) Proteins are crosslinked to chromatin (top) or DNA damage
is induced (bottom). This DNA or chromatin is extracted, sonicated and
split into two samples. (b) IP is carried out on one sample to separate the
chromatin bound factor of interest (top) or damaged DNA (bottom).
(c) Both samples are purified, amplified by PCR and differentially labelled
with red or green fluorophores. (d) The samples are allowed to hybridise to
the microarray probes and the resulting intensity values from the scanned
image are converted to numerical values. (e) These values may be plotted
and processed as required by the investigation.
www.nature.com/scientificreports
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Measuring DNA damage on DNA microarrays. To determine the
levels and locations of DNA damage, the human and yeast derived
samples were hybridised to two-colour Agilent 4x44K microarrays.
Human samples were analysed on a custom-designed microarray
covering a randomly selected section of the genome: 10 Mbp of
chromosome 17. Yeast samples were analysed with the G4493A
whole genome microarray. Log2 IP:IN ratio values are used for all
analyses giving relative levels of DNA adducts detected at the
genomic locations represented by the probes on the microarray.
Data from files created by Agilent’s Feature Extraction Software
(version 10.10) were loaded into R for analysis. Reproducibility
was assessed by calculating Spearman’s rank correlation
coefficients between datasets (Table 1), demonstrating the range of
correlation values for the respective categories described. The
average of two human in vitro cisplatin treated datasets is shown
as a Circos plot in Fig. 2a, demonstrating the heterogeneity of the
DNAdamage distribution over the 10Mbp genome section analysed.
A 25 Kbp section of the data is shown in more detail in Fig. 2b,
showing the mean and standard error of the mean of the two
datasets. Overall reproducibility is also shown as a scatter plot of
one dataset against the other for the total cisplatin (Fig. 2c) and
oxaliplatin (Fig. 2d) data, with corresponding Spearman’s rank
correlation coefficient values shown in Table 1. Similar figures for
oxaliplatin and UV-induced CPD damage datasets are shown in
Supplementary Figure S3 a and b, c and d respectively.
Validating DNA damage profiles. Employing predicted DNA
damage profiles, against which the actual damage datasets are
compared, can validate the accuracy of the 3D-DIP-chip
technology. This process has been applied previously13. Cisplatin
and oxaliplatin have been shown previously to induce DNA
damage at purine bases, forming 1,2-d(GpG), 1,2-d(ApG), 1,3-
d(Gp-NpG) intrastrand crosslinks, and interstrand guanine
crosslinks in the ratio 6552557536,14,15. Similarly, UV irradiation
has been shown previously to induce damage at dipyrimidine sites,
forming CPDs at TT, TC, CT, and CC sites in the ratio
685165135316,17. These ratios were used in conjunction with the
genome sequence to predict the level of expected damage for each
probe on the microarray. Spearman’s rank correlation coefficient
values were calculated for each microarray dataset versus the
predicted pattern for comparison (Table 1). A 25Kbp section of
the human in vitro treated cisplatin dataset and predicted profile is
also shown in Fig. 3, demonstrating the level of concordance between
the two. The variability seen around position 10,320,000 is caused by
the lack of features printed on the array over this region. This is
demonstrated by the absence of grey dots that indicate the
genomic position of these features at the bottom of the figure.
Bioinformatic analysis of genetic and epigenetic genome-wide
datasets. We have shown genomic DNA damage profiles for two
different forms of DNA damage in human DNA. Genetic damage
also induces epigenetic changes in the form of histone
modifications4. To investigate how these two parameters relate to
each other in response to genotoxic exposure we treated yeast cells
with the same genotoxins. Genome plots for UV and cisplatin
damaged DNA are presented in Supplementary Fig. S4. Alongside
this we employed ChIP-chip to measure the DNA damage induced
changes in histone H3 acetylation at lysine 9, which is known to be
required for the efficient repair of UV-induced CPDs. To do this we
measured the background histone H3 acetylation levels before
inducing DNA damage and repeated these measurements after
DNA damage, in order to determine the DNA damage induced
change. Figure 4 demonstrates the results of measuring the
distribution of genetic damage induced in the genome by exposing
yeast cells either to UV light or to treatment with cisplatin. Different
DNA damage profiles are generated from these different damaging
agents as demonstrated by the negative Spearman’s rank correlation
(Figure 4a. See also Supplementary Fig. S4), which reflects the fact
that different DNA damaging agents induce damage at different
dipyrimidine and dipurine bases. Indeed, by analysing and plotting
the same data in relation to transcriptional start sites located
throughout the genome (Figure 4b) it is possible to visualise the
different patterns of cisplatin damage (solid black line) versus UV
induced damage (solid green line). By plotting the predicted damage
spectra for both cisplatin (dashed black line) and UV (dashed green
line) inducedDNAdamage, as expected, it can be seen that the actual
damage profile generally follows the predicted pattern. Significantly
however, regions where these patterns deviate from the prediction
can be observed, particularly in the promoter regions of genes
upstream of the transcriptional start site, but also at specific
locations in the open reading frames. This is particularly evident in
the case of cisplatin damage where lower levels of damage are
observed in the promoter regions of genes than might be expected
based on the predicted pattern (see Discussion). This result
demonstrates the significance of this technique as a tool for
analysing DNA damage throughout genomes. Analysis of the
spectrum of DNA damage-induced histone acetylation reveals a
positive association between the UV versus the cisplatin induced
DNA damage treatments (Figure 4c). As expected, this is
confirmed when plotting the same data in relation to all genomic
transcription start sites (Figure 4d). However, plotting the data in this
context reveals the genomic location of a peak of DNA damage
induced histone H3 acetylation that is observed immediately
downstream of the transcription start site, just inside the open
reading frame. These results indicate that the DNA damage-
induced increase in histone H3 acetylation, which is known to be
important for the response to and repair of DNA damage in
chromatin, appears to be very similar, regardless of the individual
patterns of DNA damage induced, or whether a physical or chemical
DNA damaging agent is used. This may reflect DNA damage-
induced changes in the epigenome and chromatin structure that
Table 1 | Spearman’s rank correlation r values for 3D-DIP-Chip data of physically and chemically induced DNA damage in human and
yeast samples treated in vivo and in vitro. Correlations with prediction are calculated from the predicted profiles created in Sandcastle.
Correlations between replicates are calculated from two individual microarray datasets. UV induced DNA damage in yeast was not
investigated here.
Human correlations between: Yeast correlations between:
Treatment 3D-DIP-Chip and prediction 3D-DIP-Chip replicates 3D-DIP-Chip and prediction 3D-DIP-Chip replicates
Cisplatin In vivo 0.61 0.82 0.54 0.54
In vitro 0.67 0.92 0.56 0.72
Oxaliplatin In vivo 0.40 0.74 0.53 0.55
In vitro 0.41 0.59 0.51 0.55
UV In vivo 0.51 0.77 - -
In vitro 0.56 0.85 - -
www.nature.com/scientificreports
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are common to different DNA damaging agents and could provide
insight into how these events are organised in the epigenome.
Discussion
We have developed a method for measuring genomic DNA damage
on microarrays. We first introduced the concept to measure CPD
induction in S. cerevisiae following exposure to UV irradiation13. In
the current report we have extensively modified, adapted and, most
importantly, validated, this 3D-DIP-chip assay for use in both
human and yeast cells to measure different types of DNA damage
with sensitivity and at a high resolution over the entire yeast genome
and a 10 Mbp section of the human genome. This represents a sig-
nificant technological advance in the measurement of genetic
damage at a high resolution on a genomic scale. The key methodo-
logical modifications made to the original 3D-DIP-chip assay, which
allowed successful measurement of DNA damage in human cells can
be summarised by developments in two key areas. Firstly, the DIP
protocol was optimised by improving the immunoaffinity capture
stage. This involved increasing the stringency of the post IP washes,
and using a phenol-chloroform based post-DIP purificationmethod.
Secondly, an alternative method was used for amplifying the DIP
sample prior to microarray hybridisation using a proprietary whole
genome amplification method (WGA2, Sigma-Aldrich) instead of
ligation-mediated PCR. This advance in the application ofmicroarray-
based technology now offers a novel method and protocol for exam-
ining DNA damage in human and other cells. The detailed methods
that we describe here provide the basis for the analysis of many other
types of DNA damage to which antibodies have been, or could be
produced, opening the way to the genome-wide analysis of the full
spectrum of genetic lesions.
The method is a significant advance compared to existing
technologies, and represents an important new application of micro-
arrays. Current technologies can measure DNA damage at high-
resolution in single genetic loci at individual nucleotide resolution.
These include the use of sequencing gels18. In addition, low-
resolution methods such as immuno-slot-blot assays of total geno-
mic DNA samples are also used19. The high-resolution techniques
cover only very small sections of a genome and the low-resolution
techniques do not offer sufficient sensitivity to be of use in many
industrial applications, particularly in clinical and genotoxicity test-
ing scenarios. It is worth noting that next generation sequencing
technologies may in the future offer an alternative to the use of
microarrays following the 3D-DIP stage of the protocol and we are
indeed currently examining this. Others have already established
Figure 2 | Human in vitro platinum induced DNA damage. (a) Circos plot of the whole dataset demonstrating the heterogeneity of the damage pattern.
(b). 25Kbp section of data (produced in Sandcastle), showing themean (black line) and standard error (grey shading) of two datasets and probe positions
(grey dots). (c) and (d) Scatter plots showing the relationship between cisplatin and oxaliplatin repeat datasets respectively (plot (d) has been scaled to the
same axis limits as plot (c), resulting in a small number of probes not being shown).
Figure 3 | Validating the 3D-DIP-Chip data. Section of human chromosome 17 showing mean (black line) and standard error (grey shading) of two
cisplatin induced DNA damage datasets along with the predicted profile (red line) based on the genome sequence.
www.nature.com/scientificreports
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techniques formeasuring double strand breaks using next generation
sequencing20, using a technique that identifies the location of the
DNA double strand breaks. We have developed a high-resolution
technology, which can measure and locate DNA damage induction
across a whole genome simultaneously. This now offers a functional
assay capable of examining the DNA damaging lesions directly with
significant relevance in the fields of genotoxicity testing, translational
and personalised medicine, as well as in basic mechanistic laboratory
studies investigating DNA damage and repair. For example, we are
now using this method to examine clinical samples to characterise
genomic DNA damage signatures that could be used as predictive
biomarkers of response to the effects of DNA damaging chemother-
apeutic agents, which may subsequently allow personalised therapy.
Using platinum-induced DNA damage and UV-induced CPD
formation as a paradigm for DNA damage, we validate DIP in cap-
turing damaged DNA fragments with highly reproducible qRT-PCR
data. We confirm this by comparing our experimental data with the
predicted DNA damage patterns derived from algorithms developed
following the use of other techniques formeasuring damage in naked
DNA. Furthermore, we report the detailed protocols for the mea-
surement of two important sources of DNA damage; environmental
UV radiation and cisplatin and oxaliplatin used extensively in
chemotherapy treatment regimens for patients with solid tumours.
The ability to examine platinum-inducedDNAdamage and its repair
using these methods will offer important mechanistic and clinical
information relating to the use of these drugs, particularly with
regard to drug resistance for this therapy. As described, our approach
allows us to map DNA damage events across whole genomes and to
detect regions of preferential damage induction and repair within the
genome, offering insight into themechanisms of drug resistance. The
data we show in Figure 4 for example demonstrates the power of
these analyses by highlighting the genome-wide relationships for
both the damage induced histone H3 acetylation pattern and UV
versus cisplatin induced damage patterns respectively (Figure 4 a and
b). More importantly, however, are the subtle differences that can be
discerned by plotting the data in relation to genomic locations such
as transcription start sites as shown in Figure 4 b and d. Examining
the data in this way enables differences in genetic and epigenetic
changes to be detected according to their genomic location. These
deviations from the predicted pattern are unlikely to be caused by
repair of DNA damage in these regions in this case, since the data is
derived from the DNA of cells, which was extracted immediately
after DNA damage treatment. A possible explanation for the depar-
ture from the predicted pattern is that the in vivo induced damage
pattern may be affected by differences in the epigenome and chro-
matin structure at specific genomic locations, which is not accounted
for by the predicted pattern, since these are determined from data
derived from DNA damage frequencies measured in naked DNA.
Understanding DNA damage in the context of chromatin is fun-
damental for determining the impact of the chromatin structure
on the extent and pattern of genome-wide DNA damage. How chro-
matin structure influences DNA damage induction throughout
whole genomes and how epigenetic responses relate to the genomic
damage induction remains to be determined. We present histone
Figure 4 | Examples of the types of analyses that may be undertaken with 3D-DIP-Chip and ChIP-chip. Scatter plots show an inverse association
between cisplatin andUV inducedDNAdamage (a) but a positive association between cisplatin andUV induced histone acetylation (c). Plotting the data
around transcription start sites (TSSs) shows different patterns of damage induction with the two damaging agents (b; UV solid green line, cisplatin solid
black line) along with similar predicted patterns (UV dashed green line, cisplatin dashed black line). Standard errors for all TSSs are shown as a shaded
region. Histone acetylation around the same TSSs shows similar patterns with both damaging agents (d; same colouring as b).
www.nature.com/scientificreports
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H3K14 acetylation data in response to UV and platinum exposure as
a paradigm for how this can be achieved.We confirm histone H3K14
acetylation to be a prominent histone modification taking place
globally in the genome following exposure to two different DNA
damaging agents and that this response is remarkably consistent in
the case of these two types of DNA damage. These results dem-
onstrate the significant advantages of our method to understanding
the effects of DNA damage on the epigenome at the genomic scale.
Furthermore, this technology can be considered as a paradigm for
examining other DNA damages, providing that specific antibodies
against that damage, or some other means of affinity capturing the
damage, are available. As mentioned, this technology also has impli-
cations in the field of genotoxicity testing, where assessments of the
efficacy and toxicity of new compounds are often still made based on
simple laboratory assays or animal models. Our assay could be help-
ful in defining targets of new chemotherapeutic agents, delineating
target sequences for DNA damage and detecting the unintended
genomic damage, the so-called off-targets, caused by new pharmaco-
logy agents, such as those targeting the epigenome. Finally, next
generation sequencing technologies are offering remarkable insight
into the acquisition of mutations in genomes including cancer gen-
omes. The results of these analyses appear to reveal the life history of
mutagen exposure and, in addition, clearly reflect the associated
DNA repair capacity of the cells in question. The 3D-DIP-chip assay
described here could be used to further refine our understanding of
the mechanisms of mutation, offering the possibility of identifying
predictive DNA damage and repair signatures associated with sub-
sequent mutational end-points and tumourigenesis.
Methods
Platinum analogue chemotherapy drugs. Cisplatin and oxaliplatin were obtained
courtesy of the pharmacy department of Velindre Cancer Centre, Cardiff. The clinical
formulations, at a concentration of 3.3 mM for cisplatin and 12.6 mM for oxaliplatin,
were stored at 4uC. 2.5 mM cisplatin and 2.5 mM oxaliplatin treatments were used
for both the DNA in vitro and in vivo human and yeast cell treatments for the
microarray studies.
Yeast strains, culture and storage.The haploid, wild-type, S. cerevisiae strain used in
these studies was BY4742 (MATa his3D1 leu2D0 lys2D0 ura3D0). Glassware and
Yeast Extract Peptone Dextrose (YPD) media was sterilised by autoclaving at 121uC
for 15minutes, and all manipulations were undertaken in standard sterile conditions.
All incubations were conducted at 30uC at 180 rpm in an Infors HT multitron
standard incubator, unless otherwise stated. BY4742 cells were stored and grown in
YPD media. For long-term storage, cells were grown to logarithmic-phase in YPD,
glycerol was added to a final concentration of 30%, and cells were frozen at 280uC.
Pre-cultures were grown by inoculating cells in 10 ml of YPD, incubating until cells
reached stationary phase and storing these at 4uC. Pre-calculated amounts of pre-
culture were then used to inoculate large volumes of YPDmedia as required for each
experiment. For all experiments, cultures were incubated overnight to a density of 23
107 cells/ml. Cell density was calculated using a Neubauer cell counting chamber
(Hawksley).
In vivo platinum treatment of yeast cells.Wild-type yeast BY4742 cells were grown
to logarithmic-phase in YPD and collected by centrifugation at 5000 rpm for 5
minutes and resuspended in chilled phosphate-buffered saline (PBS) at a
concentration of 23 107 cells/ml. 250 ml of resuspended cells were incubated with
the required concentration of cisplatin or oxaliplatin (as mentioned above) in PBS for
4 hours, and untreated cells were incubated in PBS alone. Following incubation, cells
were immediately collected by centrifugation at 5000 rpm for 5 minutes at room
temperature andwashed twice with chilled PBS ready forDNApreparation. ForDNA
damage studies, DNA was extracted immediately following treatment of cells and for
histone H3 acetylation studies with chromatin, following treatment in PBS and
collection, cells were resuspended in YPD and placed in the incubator for 60minutes.
Preparation of yeast DNA. Both untreated and platinum treated cells were
resuspended in 5 ml of sorbitol-Tris- ethylenediamine tetra acetate (sorbitol-TE)
solution and mixed well. 0.5 ml of zymolyase 20 T (10 mg/ml in sorbitol solution)
and 0.5 ml of 0.28 M b- mercaptoethanol were added and samples mixed by shaking.
Cells were incubated overnight at 4uC. Spheroplasts were collected by gentle
centrifugation at 2000 rpm for 5 minutes at 4uC and resuspended in 5 ml of lysis
buffer/PBS 151(v/v) solution (DNA lysis buffer 4 M urea, 200 mM NaCl, 100 mM
Tris-HCl [pH 8.0], 10 mM CDTA, 0.5% SDS). 500 ml of 10 mg/ml RNase A was
added and samples were vortexed and incubated at 37uC for 1 hour. Following
incubation, 200 ml of proteinase K (10 mg/ml in TE buffer) solution was added and
samples were incubated for 2 hours at 65uC with occasional shaking. Two phenol/
chloroform (6 ml) DNA extractions and one chloroform (6 ml) DNA extraction
were carried out to ensure complete deproteinisation. Equal volumes of phenol/
chloroform were added (151 v/v), and samples shaken vigorously followed by
centrifugation at 10,000 rpm (Beckman-Coulter centrifuge, JA-20 rotor) for 10
minutes and transfer of the upper aqueous phase to 15 ml Falcon tubes. DNA was
recovered by precipitation using two volumes (12 ml) of pre-chilled 100% ethanol
and storing at 220uC overnight. DNA pellets were collected by centrifugation at
4000 rpm for 15 minutes at 4uC and resuspended in 1 ml of TE buffer. After being
completely dissolved, theDNAwas reprecipitated by adding 1 ml of pre-chilled 100%
isopropanol, with gentle shaking. DNA precipitate was removed by pipette tip,
resuspended in 1 ml of TE buffer and DNA checked for purity and amount by non-
denaturing agarose gel electrophoresis andUV spectrophotometry (NanoDrop-1000,
NanoDrop Technologies, Thermo Scientific).
In vitro platinum treatment of yeast DNA. For in vitro platinum treatment,
extracted naked genomic yeast DNA in TE was incubated with cisplatin or
oxaliplatin, added from stock solution giving the required final drug concentration.
DNA was incubated with cisplatin or oxaliplatin for 2 hours at 37uC and DNA
recovered by ethanol precipitation. Precipitation was conducted by adding 2.5 3
volume 100% ethanol, incubating at -80uC for 20 minutes, then at 220uC for 30
minutes, followed by centrifugation at 13500 rpm (Beckman-CoulterMicrofuge 22R)
for 20 minutes at 4uC. DNA pellets were washed with 75% ethanol and centrifuged a
second time at 13500 rpm for 20 minutes at 4uC. Pellets were dried using a SpeedVac
system (Thermo Savant) and resuspended in 100 ml TE prior to sonication and DIP.
Preparation of yeast chromatin. Wild-type yeast BY4742 cells were grown to
logarithmic-phase in YPD and treated in vivo as described above. Cells were treated
with 250 mM cisplatin or oxaliplatin for four hours and following treatment
resuspended in YPD for the required repair time. Cells were crosslinked using 3 ml of
37% formaldehyde, per 100 ml culture, for 10 minutes at room temperature on a
shaking platform. Crosslinking was quenched using 5.5 ml of 2.5 M glycine for 5
minutes at room temperature on a shaking platform. Cells were collected by
centrifugation at 5000 rpm for 5minutes at 4uC (Beckman- Coulter centrifuge, JA-10
rotor), and washed twice by resuspending in 40 ml of ice cold PBS and collecting by
centrifugation as before. Cells were resuspended in 1 ml FA/SDS (1PMSF) and
transferred to a 2 ml microcentrifuge tube. Cells were collected by centrifugation at
13500 rpm for 5 minutes at 4uC (Beckman-Coulter Microfuge 22R), the supernatant
was removed and the pellet was resuspended again in 0.5 ml FA/SDS (1PMSF) in a
2 ml microcentrifuge tube. Cells were mechanically lysed by adding 500 ml of glass
beads to each sample and vortexing for 10minutes at 4uC. The cell lysate was retrieved
by puncturing a hole in the 2 mlmicrocentrifuge tube with a hot needle and placing it
in a 15 ml Falcon tube and centrifuging briefly at 2000 rpm for 2 minutes at 4uC
(Eppendorf centrifuge 5810R). The glass beads were washed with 500 ml of FA/SDS
(1PMSF) and centrifuged again at 2000 rpm for 2 minutes at 4uC. Cell lysate was
transferred to a 2 ml microcentrifuge tube and centrifuged at 4000 rpm for 20
minutes at 4uC (Beckman-Coulter Microfuge 22R) to remove any soluble, non-
crosslinked proteins. The supernatant was removed and the pellet was resuspended in
1 ml FA/SDS (1PMSF) and sonicated using a BioRuptor sonicator (Diagenode) with
power set at the ‘high’ position for 8 cycles of 30 seconds on and 30 seconds off at 4uC.
Following sonication a further centrifugation was performed at 13000 rpm for 10
minutes at 4uC and the supernatant was collected and centrifuged again at 13000 rpm
for 20 minutes at 4uC (both using Beckman-Coulter Microfuge 22R). The
supernatant containing the chromatin was snap frozen in liquid nitrogen and stored
at 280uC.
Human cell lines. AG16409 (normal human dermal fibroblast) cells were obtained
from the Coriell Cell Repository (Camden, NJ, USA). AG16409 cells were transduced
with an amphotropic retrovirus expressing the catalytic subunit of telomerase, human
telomerase reverse transcriptase (hTERT). Telomerase activity was confirmed by the
telomeric repeat amplification protocol (TRAP) assay, ensuring immortalisation of
fibroblasts (AG16409) tert.
Human cell culture. All manipulations were undertaken in standard sterile
conditions and all glassware was sterilised by autoclaving at 121uC for 15 minutes.
Fibroblasts were grown as monolayers at 37uC in a humidified incubator, under an
atmosphere containing 5% CO2. Fibroblast growth media comprised Dulbecco’s
Modified Eagle Medium (DMEM: Gibco by Life Technologies, Invitrogen, Paisley,
UK), supplemented with 10% fetal calf serum, 1% L-Glutamine and 1% penicillin-
streptomycin (all Sigma- Aldrich, Dorset, UK). Fibroblasts were cultured in 10 ml of
growth media in T75cm 2 cell culture flasks or in 5 ml of media in T25cm 2 cell
culture flasks and replenished with fresh growthmedium approximately every 3 days.
Cells were reseeded and maintained in new cell culture flasks approximately every 4
weeks and were seeded and cultured on tissue culture dishes for drug treatments.
Fibroblasts were routinely passaged close to confluence (,80–90% confluent) every
7-10 days, when cells were trypsinised and ,2 3 105 – 4 3 105 cells were reseeded.
Briefly, cells were trypsinised by removing growth media from the flask followed by
washing with 2 ml of warmed PBS to remove residual media and serum. 2 ml of 1 X
trypsin-EDTA (Gibco by Life Technologies, Invitrogen) was added and fibroblasts
were returned to the incubator at 37uC for 15–30 minutes. When cells had detached
from the surface of the flask they were resuspended in the required amount of growth
media for reseeding. Cells were counted using an improved Neubauer
haemocytometer (Hawksley) and 10 ml of cell suspension was pipetted under the
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coverslip of the haemocytometer. For these cells the PD was ,0.4 PD/day and this
remained constant throughout these experiments.
Preparation of human DNA and in vivo platinum treatment and UV irradiation.
Approximately 23 105–43 105 cells were seeded on to tissue culture dishes (1003
20 mm), yielding approximately 2 3 106 cells following growth for 7–10 days.
Alternatively, larger tissue culture dishes (1503 25 mm) would yield 4–53 106 cells
after 10 days incubation. Cells were grown to confluence before treatment in each
case.
Stock solutions of cisplatin and oxaliplatin were diluted to the required concen-
tration using serum-free media. Growth media was removed from cells in tissue
culture dishes, cells were washed twice with 2 ml of warmed PBS (5 ml PBS used for
the larger tissue culture dishes), and serum-free media containing the platinum
analogue at the required concentration was added. Dishes were returned to the
incubator for 2 hours at 37uC. Untreated cells were also incubated for 2 hours in
serum-freemedia. Following incubation, cells were harvested with 1 x trypsin-EDTA.
PBS was added to the cell suspension and this was transferred to a 15 ml Falcon tube
and centrifuged at 1000 rpm for 5 minutes at room temperature (Eppendorf cent-
rifuge 5810R). The supernatant was removed from the cell pellet and the cells pro-
cessed directly for DNA extraction using the Qiagen DNeasy Blood & Tissue Kit
(Qiagen No. 69504).
For UV treatment, growth media was removed and cells were washed twice with
2 ml of warmed PBS. 5 ml of PBS was then added to the tissue culture dish for UV
treatment, and untreated cells were also placed in 5 ml of PBS. Cells were irradiated
with 254 nmUVC irradiation from a calibrated germicidal VL-21Gmineralight lamp
(UV products, San Gabriel, CA, USA) at a fluence of 10 J/m2/s for 5 seconds, giving a
total dose of 50 J/m2. Following treatment cells were immediately harvested using
trypsin and genomic DNA was extracted using the Qiagen DNeasy Blood & Tissue
Kit.
Human DNA treated in vitro with platinum and UV irradiation. Cisplatin or
oxaliplatin was added from stock solution to genomic DNA (suspended in buffer AE,
the elution buffer solution of the Qiagen DNeasy Blood & Tissue Kit), to give the
required final drug concentration. DNA was incubated with cisplatin or oxaliplatin
for 2 hours at 37uC and recovered by ethanol precipitation. Precipitation was
conducted by adding 2.5 3 volume 100% ethanol, incubating at 280uC for 20
minutes, then at220uC for 30 minutes, followed by centrifugation at 13500 rpm for
20minutes at 4uC (Beckman-CoulterMicrofuge 22R). DNA pellets were washed with
75% ethanol and centrifuged a second time, at 13,500 rpm for 20 minutes at 4uC.
Pellets were dried using the SpeedVac system (Thermo Savant) and resuspended in
100–200 ml of the buffer AE elution buffer prior to sonication and DIP.
For UV treatment genomic DNA, in buffer AE, was transferred to 35 3 10 mm
tissue culture dishes and irradiated as described in previous section with UV at a dose
of 300 J/m2. Following treatment, DNA was returned to microcentrifuge tubes
(Eppendorf) for fragmentation with sonication followed by DIP.
DNA and chromatin fragmentation by sonication. DNA and chromatin were
fragmented using a BioRuptor sonicator (Diagenode). Four 1.5 ml microcentrifuge
tubes, each containing 200 ml of DNA or chromatin sample, were placed in a 1.5 ml
microtube unit, and the unit placed in a cooling water bath. For human DNA each
sample was diluted to 100 ng/ml prior to sonication to ensure reproducibility. Power
was set at the ‘high’ position and sonication was conducted at 4uC. The number of
cycles of sonication employed was different between samples, firstly because
chromatin fragments more readily than naked DNA and therefore fewer cycles are
required. Secondly, for human samples a shorter fragment length was required to
improve microarray resolution. For yeast studies, a fragment length of 300–500 bp
was used, whilst for human studies a shorter fragment length of 200–300 bp was
required. Sonication schedules employed were as follows:-
Yeast DNA - 20 cycles of 30 seconds on, 30 seconds off
Yeast chromatin - 8 cycles of 30 s on, 30 s off
Human DNA - 25 cycles of 30 s on, 30 s off
Satisfactory sonication was confirmed by gel electrophoresis using a 1.2% agarose
gel and using the FastRulerTM low range DNA ladder (Fermentas) for reference.
Quantitative real-time PCR (Q-PCR). Quantitative real-time PCR was performed
using the iQTM SYBRgreen supermix (Bio- Rad) and the iCycler MyiQTM real-time
PCR detection system (Bio-Rad). For yeast qRT-PCR studies, primers for the
promoter of theMFA2 gene were used and for human studies primers for the human
28S ribosomal RNA gene were used. For yeast studies the qRT-PCR reaction was
performed using the following PCR program: 1. 95uC for 3 minutes, 2. 95uC for 15
seconds, 3. 55uC for 20 seconds -followed by plate reading. Steps 2–3were repeated 44
times. In addition amelt curve was undertaken to ensure a single PCR product and all
samples were amplified in triplicate. For human studies the qRT-PCR reaction was
performed using the following PCR program: 1. 95uC for 3 minutes, 2. 95uC for 10
seconds, 3. 60uC for 20 seconds - followed by plate reading. Steps 2–3 were repeated
44 times.
The MFA2 promoter primer sequences:-
Forward: 59 - AAAGCAGCATGTTTTCATTTGAAACA - 39
Reverse: 59 - TATGGGCGTCCTATGCATGCAC - 39
The 28S rRNA primer sequences:-
Forward: 59 - CGCAATACGAATGCCCCCG - 39
Reverse: 59 - AGCCGCCTGGATACCGC - 39
DNA immunoprecipitation damage of platinum-induced DNA damage.
Fragmented yeast or humanDNA treated in vivo or in vitrowith platinum analogues,
as described, was used for DIP using the anti-cisplatin modified DNA, CP9/19,
antibody (ab103261, Abcam). 40 ml of Dynabeads (Sheep anti-Rat IgG, Invitrogen)
per sample were washed three times using 500 ml PBS-BSA (0.1% of BSA). Washed
Dynabeads were resuspended in 50 ml of PBS-BSA (0.1% of BSA) per sample and
0.5 mg of CP9/19 antibody was added per 40 ml of Dynabeads for the detection of
cisplatin-induced DNA damage or 1.5 mg of antibody added per 40 ml of Dynabeads
for the detection of oxaliplatin-induced damage. Dynabeads and antibody were
incubated at 30uC for 30 minutes at 1300 rpm in a thermomixer (Eppendorf).
Dynabeads were collected, washed three times with 500 ml of chilled PBS-BSA (0.1%
of BSA) and resuspended in 50 ml of PBS-BSA (0.1% of BSA) per sample. 30 ml of 10 X
PBS-BSA (1% of BSA) and 6 mg of sonicatedDNAwere added to each tube containing
the Dynabeads, and the final volume made up to 300 ml with PBS. Samples were
incubated at 21uC for 3 hours at 1300 rpm in a thermomixer. Following incubation,
samples underwent a series of washes as follows: first wash with 500 ml of freshly
prepared FA/SDS buffer. This was followed by three washes with 500 ml of FA/SDS
containing 0.5 M NaCl (for yeast samples) or 1 M NaCl (for human samples), one
wash with 500 ml of LiCl solution and one wash with 500 ml of cold TE. DNA was
eluted from the Dynabeads in 125 ml of 1 x pronase buffer at 65uC at 900 rpm for
30 min in a thermomixer (Eppendorf). 6.25 ml of pronase (20 mg/ml) was added and
samples incubated in a water bath at 65uC overnight. IN samples of 0.6 mg (1/10 of IP
sample) of sonicated DNA were made up to 100 ml with TE buffer followed by the
addition of 25 ml of 5 x pronase buffer and 6.25 ml of pronase (20 mg/ml) and
incubated in a water bath at 65uC overnight. Following overnight incubation, IP and
IN samples were processed for removal of the DNA damage (see next section), and
5 ml of DNase-free RNase A (10 mg/ml) was added during this process. DNA was
then purified and for yeast samples this was achieved using the PureLink TM Quick
PCR Purification Kit (Invitrogen) and eluted in 50 ml of elution buffer and for human
DNA samples it was achieved using a phenol-chloroform extraction method. Finally,
to increase the overall DNA yield in the human DIP samples, DIP samples were
processed in parallel and two samples pooled prior to the qRT-PCR stage.
Removal of platinum adducts prior to qRT-PCR andmicroarray preparation.DIP
DNA fragments detected by the CP9/19 antibody and the corresponding IN DNA
samples will contain platinum adducts (apart from untreated samples), which are
known to inhibit DNA polymerase function and interfere with microarray
hybridisation. These samples therefore require processing for removal of these
adducts prior to downstream applications. Platinum-DNA adducts are very stable
over a long period of time, but in the presence of cyanide ions most platinum residues
are known to be removed from DNA10. Sodium cyanide (NaCN) has been proven to
be the most effective chemical for disrupting platinum-DNA adducts10–12 and in the
DIP studies described in this paper, NaCN was used to remove platinum adducts.
Following overnight incubation of the IP and IN samples with pronase DNA samples
were incubated with 0.2 M NaCN for 2 hours at 65uC. 5 ml of RNase A (10 mg/ml)
was added for the last 45 minutes of this incubation. Following incubation, DNA
samples were purified as described in the previous section.
Removal of CPDs prior to qRT-PCR and microarray preparation. Similar to work
examining the platinum adducts, CPDs also needed removal prior to qRT-PCR,
WGA and microarray hybridisation and this was achieved using the proprietary
PreCR DNA repair kit (New England Biolabs) - a kit that removes many DNA
damages including CPDs. 40 ml of IP and IN samples were processed for repair using
this kit as per the manufacturer’s instructions. Following repair, DNA was purified
using phenol-chloroform extraction and ethanol precipitation and resuspended in
10 ml.
Chromatin immunoprecipitation of histone H3K14 acetylation. Yeast chromatin
extracted from cells treated in vivo with platinum analogues was used for chromatin
immunoprecipitation (ChIP) using the anti-acetyl-histone H3(lysine14) antibody
(Millipore, 07-353). 50 ml of Dynabeads (Sheep anti-Rabbit IgG, Invitrogen) per
sample were washed three times using 500 ml PBS-BSA (0.1%). Washed Dynabeads
were resuspended in 50 ml of PBS-BSA (0.1%) per sample and 2 ml of anti-acetyl-
histone H3 (lysine14) antibody was added per 50 ml of Dynabeads for detection of
histone H3 K14 acetylation. Dynabeads and antibody were incubated at 30uC for 30
minutes at 1300 rpm in a thermomixer (Eppendorf). Dynabeads were collected,
washed three times with 500 ml of chilled PBS-BSA (0.1%) and resuspended in 50 ml
of PBS-BSA (0.1%) per sample. 30 ml of 10 X PBS-BSA (10 mg/ml) and 125 ml of
sonicated chromatin were added to each sample containing the Dynabeads, and the
final volumemade up to 300 ml with PBS. Samples were incubated at 21uC for 3 hours
at 1300 rpm in a thermomixer. Following incubation, samples underwent a series of
washes as follows: first wash with 500 ml of freshly prepared FA/SDS buffer. This was
followed by three washes with 500 ml of FA/SDS 1 500 mM NaCl, one wash with
500 ml of LiCl solution and one wash with 500 ml of cold TE. Chromatin was eluted
from the Dynabeads in 125 ml of pronase buffer at 65uC at 900 rpm for 30 min.
6.25 ml of pronase (20 mg/ml) was added to each sample and incubated at 65uC in a
water bath overnight. IN samples of 25 ml of sonicated chromatin were made up to
100 ml with TE buffer followed by the addition of 25 ml of 5 x pronase buffer and
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6.25 ml of pronase (20 mg/ml) and incubated overnight as the IP samples. Following
overnight incubation, IP and IN samples were processed for damage removal with
sodium cyanide as discussed previously, and 5 ml of DNase- free RNase A (10 mg/ml)
was added during this process. DNAwas purified using the PureLink TMQuick PCR
Purification Kit (Invitrogen) and eluted with 50 ml elution buffer.
Sample Preparation for yeast DNAmicroarray hybridisation. Yeast DIP and ChIP
and input samples were processed for microarray hybridisation as described in the
Agilent Technologies Yeast ChIP on chip protocol (Agilent Technologies Yeast ChIP-
on-chip Analysis Protocol, version 9.2), and as outlined previously14. Briefly, the steps
required are blunting of the ends of the DNA fragments followed by ligation of a
common linker sequence of DNA to the ends of these fragments, ligation-mediated
PCR amplification (LM-PCR), labelling and hybridisation to 43 44k format Agilent
yeast microarrays. Following amplification the concentration of DNA was measured
with the NanoDrop spectrophotometer and sample concentration was normalised to
150 ng/ml with H2O. 10.5 ml of the IP and IN samples were differentially fluorescently
labelled with Cy5 and Cy3 fluorophores respectively using the BioPrime Total
Genomic Labelling System (Invitrogen), which yields sufficient quantities of labelled
DNA for hybridisation to microarrays. For labelling, samples were incubated for
2 hours at 37uC. Labelling efficiency was determined using the MicroArray
Measurement Module on the NanoDrop ND-1000 Spectrophotometer, which
measures DNA concentration and labelling effectiveness. Following labelling, the IP
and IN samples were combined and 110 ml of the hybridisation mixture applied to
each Agilent yeast 4 3 44k microarray. Mixtures were allowed to hybridise to
microarrays for 24 hours at 65uC. The 43 44kmicroarray format signifies that 44,000
features are imprinted on a single microarray to represent the entire yeast genome and
that 4 microarrays are printed on each glass slide. The method for each of the
preparatory microarray steps of DNA end-blunting, linker ligation, PCR
amplification, labelling and hybridisation were all conducted as described previously14.
Sample Preparation for human DNA microarray hybridisation. Human samples
were prepared for microarray hybridisation differently to yeast samples. A
proprietary whole genome amplification method GenomPlex Complete Whole
Genome Amplification Kit (WGA2, Sigma-Aldrich) was used for amplification
rather than LM-PCR. This removed the need for a second round of PCR amplification
preventing the introduction of amplification bias. This kit uses an amplification
method based on conversion of genomic DNA fragments into PCR-amplifiable
OmniPlex librarymolecules flanked by universal priming sites. The OmniPlex library
is then PCR amplified using universal oligonucleotide primers to generate a
representative amplification of human genomic DNA.
The manufacturer’s protocol was followed except that the initial fragmentation
step was eliminated since our samples were already fragmented. The entire DIP
sample was used for library preparation and 2 ml of 1 x library preparation buffer and
1 ml of library stabilization solution were added to the DIP sample, followed by
mixing and incubating at 95uC for 2 minutes and immediately cooling on ice. 1 ml of
library preparation enzyme was added to each sample, and samples incubated in a
thermal cycler at 16uC for 20 minutes, 24uC for 20 minutes, 37uC for 20 minutes and
75uC for 5 minutes before proceeding to PCR amplification. 7.5 ml of 10 X amp-
lification master mix, 47.5 ml of nuclease-free H2O and 5 ml of WGA DNA poly-
merase were added to each sample, mixed and incubated in a thermal cycler as
follows: 95uC for 3 minutes, followed by 14–16 cycles of 94uC for 15 sec and 65uC for
5 minutes. Samples were purified using the PureLink PCR Purification Kit
(Invitrogen), eluted in 15 ml of water and DNA quantified using the MicroArray
MeasurementModule on the NanoDrop ND-1000 Spectrophotometer. The expected
yield was between 1–5 mg of genomic material, providing enough material for one
microarray experiment. Following amplification, samples were labelled as described
before using the BioPrime Total Genomic Labelling System (Invitrogen) except that
human samples were labelled for 3 hours at 37uC. Multiple labelled IP DNA samples
could be combined prior to microarray hybridisation as a means to boosting the
microarray signal and samples were hybridised as described above for 24 hours at
65uC to custom-designed Agilent Technologies human 4 3 44k microarrays.
Microarray washing, scanning and feature extraction. After hybridisation both the
yeast and human microarrays were washed twice and scanned as described in the
Agilent Technologies Yeast ChIP on chip protocol (Agilent Technologies Yeast ChIP-
on-chip Analysis Protocol, version 9.2). The scanned image was analysed by Agilent
Feature Extraction computer software, which converted the image into numerical
values for data analysis. Microarray data analysis was conducted using the R statistical
programming language (R version 2.15.2). All of the analysis presented in this paper
was conducted using R using software developed in our laboratory.
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